Published 2016 | Version v1
Publication

Heparin for the treatment of thrombosis in preterm and term neonates

Description

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess whether heparin treatment (both UFH and LMWH) in preterm and term newborn infants with diagnosed thrombosis reduces the rate of mortality and morbidity. The intervention will be compared to placebo or no treatment. In addition, the safety of heparin therapy (both UFH and LMWH) will be assessed for potential harms. Subgroup analyses will be performed regarding gestational age, birth weight, mode of thrombus diagnosis, presence of central line, positive family history for genetic disorders (thrombophilia, deficiency of protein S and protein C, MTHFR mutation), route of heparin administration, type of heparin used, and location of thrombus (see Subgroup analysis and investigation of heterogeneity).

Additional details

Created:
February 14, 2024
Modified:
February 14, 2024